The agreement sets terms under which POC will manufacture the product or receive royalties
iSolveSM information on demand is the result of our focus on customer relationship
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
An accomplished R&D leader and champion of the application of AI to drug discovery
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The deal includes upfront payments, milestone payments and ongoing royalties
Subscribe To Our Newsletter & Stay Updated
